Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.71 USD
Change Today +0.57 / 4.34%
Volume 590.1K
As of 1:49 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/9/14 - $35.52
52 Week Low
10/7/15 - $12.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

307 Employees
Last Reported Date: 08/17/15
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Medical Officer
Total Annual Compensation: $405.0K
Chief Performance Officer
Total Annual Compensation: $341.3K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 10:15 AM

Aegerion Pharmaceuticals, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 10:15 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Eric Curtis, President of U.S. Commercial, Gregory D. Perry, Chief Financial Officer, Sandford Drexel Smith, Interim Chief Executive Officer, Director and Member of Audit Committee.

Aegerion Pharmaceuticals Appoints Donald K. Stern to Board of Directors

Aegerion Pharmaceuticals, Inc. has appointed Donald K. Stern, Esq., to its Board of Directors, effective immediately. Mr. Stern will serve as a Class III director and will be up for re-election to the Board of Directors in 2016. Mr. Stern is Managing Director of Corporate Monitoring & Consulting Services at Affiliated Monitors Inc.

Aegerion Pharmaceuticals, Inc. announced delayed 10-Q filing

On 08/11/2015, Aegerion Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $13.71 USD +0.57

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Isis Pharmaceuticals Inc $41.63 USD -0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at